Longevity Health Holdings, Inc. (XAGE) Stock Price & Analysis
Longevity Health Holdings, Inc. (XAGE) fell 21.87% to USD 0.25 as of June 10, 2026 at 04:16 UTC, according to Nexqual real-time market data.
XAGE last closed at USD 0.32; the session ranged USD 0.25–0.25 on volume of 50 shares. Market capitalization is $618,830, with a 52-week range of USD 0.23–8.27 (OQB). Source: Nexqual, June 10, 2026 at 04:16 UTC.
Key Statistics (as of June 10, 2026 at 04:16 UTC)
| Price | USD 0.25 |
|---|---|
| Change | ▼ 21.87% (down) |
| Previous Close | USD 0.32 |
| Open | USD 0.25 |
| Day Range | USD 0.25 – 0.25 |
| 52-Week Range | USD 0.23 – 8.27 |
| Volume | 50 shares |
| Market Cap | $618,830 |
| Exchange | OQB |
Technical Analysis (XAGE)
Nexqual's technical model rates XAGE "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 04:16 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 47.69 (neutral) |
| vs SMA50 | Below (USD 0.33) |
| MACD | -0.01 (negative) |
Analyst Ratings (XAGE)
Wall Street analysts rate XAGE "None", per Nexqual as of June 10, 2026 at 04:16 UTC.
| Consensus Rating | None |
|---|
Earnings (XAGE)
Source: Nexqual, June 10, 2026 at 04:16 UTC.
Financials & Fundamentals (XAGE)
| Total Revenue | $1.79M |
|---|---|
| Revenue Growth (YoY) | -23.20% |
| Gross Margin | +67.69% |
| Operating Margin | -389.31% |
| Profit Margin | +0.00% |
| Current Ratio | 0.15 |
| Total Cash | $313,396 |
| Total Debt | $400,615 |
| Free Cash Flow | $-513,088 |
Source: Nexqual, June 10, 2026 at 04:16 UTC.
Financial Health Score (XAGE)
Nexqual rates Longevity Health Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 04:16 UTC.
| Growth | Critical — Revenue -23% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $313K cash, no debt |
| Cash Flow | Weak — FCF negative: -$513K, burning cash |
| Efficiency | Mixed — No data |
Ownership (XAGE)
| Insider Ownership | +36.10% |
|---|---|
| Institutional Ownership | +0.75% |
| Shares Outstanding | 2.48M |
| Float | 1.67M |
| Short % of Float | +0.59% |
Source: Nexqual, June 10, 2026 at 04:16 UTC.
Leadership (XAGE)
Longevity Health Holdings, Inc. is led by Janakiram Ajjarapu (age 56), CEO & Chairman, per Nexqual as of June 10, 2026 at 04:16 UTC.
| CEO & Chairman | Janakiram Ajjarapu (age 56) |
|---|---|
| Chief Financial Officer | Bryan J. Cassaday (age 56) |
| Founder and Chief Scientific Officer | Phil Campbell |
Major Backers & Investors (XAGE)
Notable institutional backers of Longevity Health Holdings, Inc. include DRW Securities, LLC, Carnegie Mellon University, according to Nexqual as of June 10, 2026 at 04:16 UTC.
Active Investors
| Investor | Stake |
|---|---|
| DRW Securities, LLC | 0.57% |
| Carnegie Mellon University | 0.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.32% |
Source: Nexqual, June 10, 2026 at 04:16 UTC.
From Longevity Health Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- What constitutes a reasonable basis can vary depending on the strength or type of claim made, or the market in which the claim is made, but objective evidence substantiating the claim is generally required.   Regulation of BHA and THA In the United States, biological products, including our BHA and THA products, are licensed by the FDA for marketing under the Public Health Service Act (the "PHS Act") and regulated under the FDCA.
- In addition, the intellectual property related to our BHA and THA products includes twenty-one patents that include exclusive, worldwide licenses from CMU.   Government Regulation Regulation of Cosmetics We and our products are subject to various federal, state and international laws and regulations, including regulation in the United States by the FDA, the Consumer Product Safety Commission and the Federal Trade Commission (the "FTC").
- We also rely on and use commercially reasonable measures to protect our unpatented proprietary technology, which includes our expertise and product formulations, continuing innovation, and other know-how to develop and maintain our competitive position.
- Our formulation contains over a thousand growth factors, proteins, and peptides, but no live cells.   Our technology is based on the premise that a healthy human body can heal itself from simple wounds and fight against microbes.
Partnerships
- We collaborate with our suppliers to meet our stringent design and creative criteria.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BGLC | BioNexus Gene Lab Corp | USD 2.18 | ▼ 1.14% |
| ARBB | ARB IOT Group Limited | USD 5.67 | ▲ 0.98% |
| NXTS | Nexentis Technologies Inc. | USD 5.03 | ▼ 13.28% |
| ZVSA | ZyVersa Therapeutics, Inc. | USD 0.17 | ▼ 12.55% |
| NIVF | NewGenIvf Group Limited | USD 0.49 | ▼ 22.88% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:16 UTC. This page is informational and not investment advice.